Laura Sena
@laurasenamd.bsky.social
📤 349
📥 731
📝 6
Physician-scientist and prostate cancer medical oncologist at Johns Hopkins
We are excited to open a clinical trial to assess how metabolic changes induced by water-only fasting affects the immune response to prostate cancer. Spread the word – I’m happy to discuss with any interested candidates.
clinicaltrials.gov/study/NCT068...
loading . . .
ClinicalTrials.gov
https://clinicaltrials.gov/study/NCT06826924?term=NCT06826924&rank=1
7 months ago
0
2
0
reposted by
Laura Sena
Josh Lang
10 months ago
Thrilled to share a project that we envisioned over a decade ago to perform high purity/high specificity molecular analysis of circulating tumor cells! Led by the Dr. Marina Sharifi and Dr. Jamie Sperger and funded by Funded by PCF, NCI, DOD
@theaacr.bsky.social
urldefense.com/v3/__https:/...
1
7
2
reposted by
Laura Sena
American Association for Cancer Research (AACR)
10 months ago
The AACR is deeply concerned that the Administration’s recent actions are threatening NIH and its mission to accelerate progress for patients with cancer and other diseases that afflict millions of Americans. Read our statement:
https://buff.ly/4gRXNB8
3
81
62
reposted by
Laura Sena
Brendan Manning
12 months ago
But…..ok, ok, I’m convinced. Elegant and definitive.
www.science.org/doi/10.1126/...
loading . . .
Metformin targets mitochondrial complex I to lower blood glucose levels
Acute oral metformin administration lowers blood glucose levels by targeting mitochondrial complex I.
https://www.science.org/doi/10.1126/sciadv.ads5466
1
33
9
add a skeleton here at some point
12 months ago
1
7
5
reposted by
Laura Sena
David J. Einstein
about 1 year ago
Fascinating and well written! Reminiscent of a patient from our rapid autopsy cohort with targetable truncal driver but remarkable “dead-end” CNA-quiet subclones in the primary that fail to metastasize despite aggressive histology.
pubmed.ncbi.nlm.nih.gov/34568716/
add a skeleton here at some point
0
5
1
Happy to share an educational case that demonstrates that selection can drive acquired therapy resistance in metastatic prostate cancer
rdcu.be/d15Ph
Wonderful collab with
@rachelkarchin.bsky.social
@davidesanin.bsky.social
loading . . .
Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer
npj Precision Oncology - Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer
http://rdcu.be/d15Ph
about 1 year ago
0
6
3
Thanks for visiting and teaching us amazing science Nima!!
add a skeleton here at some point
about 1 year ago
1
4
2
you reached the end!!
feeds!
log in